• Link to LinkedIn
  • Link to X
  • Link to Facebook
  • Contact Us
  • Careers
Spermosens AB
  • Technology
    • IP Status
    • White Paper
  • Team
    • Core Team
    • Board
    • Partners
  • About us
    • Milestones
    • Sustainable Development Goals
    • Sponsorships & Memberships
    • Advisory Board Members
  • Investors
    • TO 6
    • The Share
    • Financial Calendar
    • Press & Media
    • Financial Reports
    • Board
    • Corporate Governance
  • Press & Media
    • Press Releases
    • Presentations
    • Interviews
    • Articles
    • Photos & Logo
  • ART Academy
  • Menu Menu

Spermosens provides an update on the Generation 3 clinical study

The Generation 3 clinical study is a central element in the Company’s strategy to demonstrate the clinical value of JUNO-Checked and to pursue commercialization through partnerships. The study evaluates JUNO-Checked, which measures the sperm cell’s ability to bind to the egg, in couples undergoing IVF treatment. The clinical data forms the basis for these partner discussions, which the Company continues to advance in parallel with the study.

Recruitment has progressed faster than expected so far, supported by a strong collaboration with the clinic and a high willingness among patients to participate. This is an encouraging marker of progress. Recruitment will pause during the clinic’s summer break and resume mid August.

In parallel with the study, the Company is adjusting the parameters of how the test is performed to produce the most accurate results. Validating a new diagnostic technology is a demanding process, and as with any clinical study the outcome and timing are not certain.

Spermosens will participate in the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London on 5–8 July 2026. The Company has been selected to present the results of its first clinical study, completed in 2025 with the second-generation JUNO-Checked sensor, and will meet companies active in the field.

Tore Duvold, CEO of Spermosens, comments, “Recruitment ahead of plan is an important step, as it provieds us the data we need to conclude the study, and it reflects a strong collaboration with the clinic and the patients participating. Presenting our first clinical study at ESHRE next week is a great opportunity to engage with the field, and completing the Generation 3 study during 2026 remains our priority.”

 

For more information, please contact:

Tore Duvold, CEO

E-mail: info@spermosens.com

 

About Spermosens AB

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company’s shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.

 

Attachments

  • 📎 Spermosens provides an update on the Generation 3 clinical study PDF
← Back to press releases
1 July, 2026
Share this entry
  • Share on X
  • Share on LinkedIn
  • Share by Mail
https://www.spermosens.com/wp-content/uploads/2021/08/Spermosens_Logo_RGB-1-1024x364.png 0 0 https://www.spermosens.com/wp-content/uploads/2021/08/Spermosens_Logo_RGB-1-1024x364.png 2026-07-01 09:52:092026-11-14 21:49:31Spermosens provides an update on the Generation 3 clinical study

Press releases

  • 12 November, 2026 Regulatory Spermosens AB (publ) INTERIM REPORT JULY – SEPTEMBER 2026 Our focus is shifting from development to go-to-market preparations   1 JULY – 30… Read more
  • 9 November, 2026 Regulatory Leading Australian fertility group Genea to run first independent clinical study of JUNO-Checked Spermosens AB has signed a collaboration framework agreement with Genea Pty Ltd (Genea), one of… Read more
  • 20 October, 2026 Spermosens presents JUNO-Checked at ASRM 2026 in Baltimore Spermosens AB (publ) (“Spermosens” or the “Company”) announces that the Company has been admitted to the … Read more
  • 1 September, 2026 Regulatory Bulletin from Extraordinary General Meeting in Spermosens AB (publ) Today, September 1, 2026, the Extraordinary General Meeting was held. Below is a summary of the… Read more
  • 21 August, 2026 Spermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026 Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live… Read more
  • 20 August, 2026 Regulatory Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026 In the second quarter of 2026, we saw recruitment into its Generation 3 clinical validation study… Read more

Spermosens AB

MEDICON VILLAGE
Scheeletorget 1
223 81 Lund, Sweden

 

  • Quality & Regulatory
  • Privacy Policy
Cookie settings
© Copyright 2025 - Spermosens AB | Photos from Unsplash.com | Icons from Flaticon.com | Website by 8612 Hemsidesproduktion
  • Link to LinkedIn
  • Link to X
  • Link to Facebook
Link to: Bulletin from Annual General Meeting in Spermosens AB (publ) Link to: Bulletin from Annual General Meeting in Spermosens AB (publ) Bulletin from Annual General Meeting in Spermosens AB (publ) Link to: Spermosens calls SEK 4.85 million under previously announced Capital Facility Link to: Spermosens calls SEK 4.85 million under previously announced Capital Facility Spermosens calls SEK 4.85 million under previously announced Capital Facili...
Scroll to top Scroll to top Scroll to top

This site uses cookies. Please accept the settings or adjust them to your personal preference.

Accept settingsHide this notificationSettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide the notification